- Politics
- Diversity, equity and inclusion
- Financial Decision Making
- Telehealth
- Patient Experience
- Leadership
- Point of Care Tools
- Product Solutions
- Management
- Technology
- Healthcare Transformation
- Data + Technology
- Safer Hospitals
- Business
- Providers in Practice
- Mergers and Acquisitions
- AI & Data Analytics
- Cybersecurity
- Interoperability & EHRs
- Medical Devices
- Pop Health Tech
- Precision Medicine
- Virtual Care
- Health equity
Fertility Focus Raises $2.7M for Real-Time, Predictive Tech
The company has also signed a deal with Sensiia to develop biosensors for women who want to get pregnant.
Fertility Focus, a startup that uses data and technology to help couples conceive, has raised $2.7 million in Series A funding, according to an announcement.
The United Kingdom-based company is best known for OvuSense, a fertility monitor that can predict ovulation up to a day in advance by measuring a woman’s core body temperature. Fertility Focus says its technology can determine the date when ovulation begins with 99 percent accuracy.
So far, patients have used OvuSense in more than 50,000 cycles. It has been on the market in the U.S. for almost five years, but the new capital is slated to advance its efforts in North American and European markets and fund new clinical trials.
>> READ: Natural Cycles Is the First FDA-Approved Contraception App. But It’s Not for All Women
“With the rich data provided by over 50,000 cycles, including women with a huge variety of cycle types, we can confidently say we’re arming women who struggle to conceive with more information about their fertility,” CEO Robert Milnes said in a statement.
Investors also appear confident in OvuSense and the direction in which Fertility Focus is headed.
Foresight Group and Coutts Investment Club led today’s funding round. Rob Jones, investment director at Foresight, joined the Fertility Focus board with great optimism for the company’s future and the market in which it operates.
“This is such a deeply personal issue for families across the globe — and many directly tie to the information only OvuSense can provide,” Jones said. “The team’s passion to improve the fertility journey for women is inspiring.”
In recent years, digital and data-driven fertility solutions have carved out a spot in the health-tech market. But some mobile health apps and fertility monitoring devices have emerged as unreliable for women with irregular cycles. Fertility Focus, on the other hand, built OvuSense specifically for those couples.
The company plans to continue to evolve its products. In today’s announcement, Fertility Focus noted that it had signed a license with Sensiia, which will develop sensors for the company. Fertility Focus said its algorithms and Sensiia’s sensors will help women get more information earlier in the process and result in less invasive monitoring.
Get the best insights in healthcare analytics directly to your inbox.
Related
FDA Approves Marketing of First mHealth Solution for Contraception
Progenity Raises $125M in Series B Financing
How the First FDA-Approved Contraception App Performs Across Populations
